Women participants in cardio-renal-metabolism trials: Actionable steps to drive lasting change
Join us at our joint session with CVCT discussing the role of women in clinical trials, and how can create long-term, sustainable change.
Date and time: Saturday December 2, 8:30am – 10:30am
Location: Global Cardiovascular Clinical Trialists Forum, The National Press Club 529 14th St NW, Washington, DC 20045
Room: Fourth Estate
Chairpersons: Mary N. Walsh (St Vincent, IN, USA), Cindy Westerhout (Edmonton, CAN)
|Women participation in drug/device clinical trials
||Roxana Mehran (New York, NY, USA)
|Exclusion by design: the role of eligibility criteria in under-representation of women in clinical trials
||Harriette Van Spall (Hamilton, Canada)
|Biological plausibility of sex differences in CV trials. Is a difference expected?
||Angela Maas (Nijmegen, NED)
|Meta-analysis of sex-based subgroup analyses in CV trials.
||Vijay Kunadian (Newcastle upon Tyne, UK)
|Differences between men and women. When, and how to demonstrate? How and when explore differences using subgroup analysis?
||Cindy Westerhout (Edmonton, CAN)
|What sex related difference is clinically meaningful? Dosing, efficacy or safety differences?
||Orly Vardeny ( Minneapolis, MN, USA)
|Are Sex – gender differences accounted for in regulatory approval?
||Terri Cornelison (FDA, USA)
||Lisa Begg (NIH, Office of Research on Women’s Health, USA)
||Lisa Salberg (HCMA, USA)